Investors & Media

Overview

Corporate Profile

Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary antibody drug conjugate, or ADC, platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients. Our lead product candidate, XMT1522, is in Phase I clinical trials. We expect that our second product candidate, XMT1536, will be entering clinical trials in early 2018. In addition, our partners are advancing their pipeline of ADCs using our platform.

  • Copyright Nasdaq. Minimum 15 minutes delayed.